Regulus Therapeutics Inc. (NASDAQ:RGLS) registered a -42.22% decrease, still its new closing price is -38.97% up from the company’s 1 year high of 8.90.It posted -42.22% losses in previous 5 sessions and is now the subject of 2 analysts who together assign a hold rating on stock. 0 of Wall Street analysts have an underperform rating; the 0 sells versus 2 buy or better ratings. The 7 stock analysts following this company have an average price target at $8.60, with individual PT in the $5.00-$13.00 range. The shares moved at $1.30, implying that brokerage firms see shares losing about -77.51% in twelve months time.
Regulus Therapeutics Inc. (RGLS) SEC Form 4 News
The stock is getting much attention these days as insiders are adding shares while they posted a -42.22% fall year to date. A COO at Regulus Therapeutics Inc. (RGLS) acquired shares in a transaction closed on Thursday March 03, 2016. Hagan Joseph P bought 10,000 shares in the company at $7.19 each and collected $71,001 in proceeds. Hagan Joseph P now owns 10,000 shares in the company after this transaction. A 10% Owner in the company, ALNYLAM PHARMACEUTICALS, INC., disclosed a transaction on Tuesday February 23, 2016 that ended up generating $7,180,000 from the sale of 1,000,000 shares at $7.18 per share.
Regulus Therapeutics Inc. (NASDAQ:RGLS) Upcoming Results on Tap
Regulus Therapeutics Inc. will next provide financial results for the March 2017 quarter. Stock analysts expect it to report per-share earnings of $-0.38 in that period. Sales during the quarter are predicted to arrive at $1.41 million.
Earnings surprise history: Last quarter, the company posted approximately $0 in revenue and EPS of $-0.37. The mean forecast was for $1.2 million and $-0.40 a share, respectively. One quarter earlier, revenue for the stock was at $0, with earnings at $-0.40/share.
Regulus Therapeutics Inc. (RGLS) Brokerage Update
Regulus Therapeutics Inc. (RGLS) is in Wells Fargo’s research list so their analyst rating change is noteworthy. These shares were downgraded to Market Perform from Outperform by Wells Fargo, according to news reported on Monday January 30, 2017.Another important research note was issued by Needham on Monday January 30, 2017.The firm downgraded RGLS to Hold from Buy. Over the last six months and over the last three months, the shares of Regulus Therapeutics Inc. (RGLS), have changed -63.59% and -52.90%, respectively.